{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:37:25Z","timestamp":1790699845337,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T00:00:00Z","timestamp":1550534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81502636"],"award-info":[{"award-number":["81502636"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008871","name":"Yunnan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["2017ZF010"],"award-info":[{"award-number":["2017ZF010"]}],"id":[{"id":"10.13039\/501100008871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["14DZ2294100"],"award-info":[{"award-number":["14DZ2294100"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:p>\n                    Poly(\n                    <jats:styled-content style=\"fixed-case\">ADP<\/jats:styled-content>\n                    \u2010ribose) polymerase (\n                    <jats:styled-content style=\"fixed-case\">PARP<\/jats:styled-content>\n                    ) enzymes play an important role in repairing\n                    <jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content>\n                    damage and maintaining genomic stability. Olaparib, the first\u2010in\u2010class\n                    <jats:styled-content style=\"fixed-case\">PARP<\/jats:styled-content>\n                    inhibitor, has shown remarkable clinical benefits in the treatment of\n                    <jats:italic>\n                      <jats:styled-content style=\"fixed-case\">BRCA<\/jats:styled-content>\n                    <\/jats:italic>\n                    \u2010mutated ovarian or breast cancer. However, the undesirable hematological toxicity and pharmacokinetic properties of olaparib limit its clinical application. Here, we report the first preclinical characterization of fluzoparib (code name:\n                    <jats:styled-content style=\"fixed-case\">SHR<\/jats:styled-content>\n                    \u20103162), a novel, potent, and orally available inhibitor of\n                    <jats:styled-content style=\"fixed-case\">PARP<\/jats:styled-content>\n                    . Fluzoparib potently inhibited\n                    <jats:styled-content style=\"fixed-case\">PARP<\/jats:styled-content>\n                    1 enzyme activity and induced\n                    <jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content>\n                    double\u2010strand breaks, G\n                    <jats:sub>2<\/jats:sub>\n                    \/M arrest, and apoptosis in homologous recombination repair (\n                    <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                    )\u2010deficient cells. Fluzoparib preferentially inhibited the proliferation of\n                    <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                    \u2010deficient cells and sensitized both\n                    <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                    \u2010deficient and\n                    <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                    \u2010proficient cells to cytotoxic drugs. Notably, fluzoparib showed good pharmacokinetic properties, favorable toxicity profile, and superior antitumor activity in\n                    <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                    \u2010deficient xenografts models. Furthermore, fluzoparib in combination with apatinib or with apatinib plus paclitaxel elicited significantly improved antitumor responses without extra toxicity. Based on these findings, studies to evaluate the efficacy and safety of fluzoparib (phase\n                    <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>\n                    ) and those two combinations (phase I) have been initiated. Taken together, our results implicate fluzoparib as a novel attractive\n                    <jats:styled-content style=\"fixed-case\">PARP<\/jats:styled-content>\n                    inhibitor.\n                  <\/jats:p>","DOI":"10.1111\/cas.13947","type":"journal-article","created":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T03:48:52Z","timestamp":1548042532000},"page":"1064-1075","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Pharmacologic characterization of fluzoparib, a novel poly(\n                    <scp>ADP<\/scp>\n                    \u2010ribose) polymerase inhibitor undergoing clinical trials"],"prefix":"10.1111","volume":"110","author":[{"given":"Lei","family":"Wang","sequence":"first","affiliation":[{"name":"Shanghai Institute of Materia Medica Chinese Academy of Sciences  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyong","family":"Yang","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Medicine Co Ltd  Lianyungang China"},{"name":"Pharmaceutical Research Center and School of Chemistry and Chemical Engineering Southeast University  Nanjing China"},{"name":"Jiangsu Province Hi\u2010Tech Key Laboratory for Biomedical Research Southeast University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengying","family":"Xie","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Materia Medica Chinese Academy of Sciences  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahua","family":"Jiang","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Medicine Co Ltd  Lianyungang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhao","family":"Gao","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Materia Medica Chinese Academy of Sciences  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Fu","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Materia Medica Chinese Academy of Sciences  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Materia Medica Chinese Academy of Sciences  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xubin","family":"Bao","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Materia Medica Chinese Academy of Sciences  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Fu","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Materia Medica Chinese Academy of Sciences  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7396-7122","authenticated-orcid":false,"given":"Liguang","family":"Lou","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Materia Medica Chinese Academy of Sciences  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,2,19]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2812"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1405005111"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1963"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03443"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.67"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S147726"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32440-6"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900212"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30469-2"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-012-9922-7"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.10.010"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv308"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30682-4"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.10.013"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2012.05.004"},{"key":"e_1_2_8_19_1","first-page":"215","article-title":"PARP inhibitors: review of mechanisms of action and BRCA1\/2 mutation targeting","volume":"15","author":"Dziadkowiec KN","year":"2016","journal-title":"Prz Menopauzalny"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.10.040"},{"key":"e_1_2_8_21_1","unstructured":"CHMP assessment report\u2010Lynparza.European Medicines Agency 2014."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.2025"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00138-8"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2017.06.006"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2119"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.24.19.8504-8518.2004"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.04.006"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcas.13947","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.13947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T17:42:26Z","timestamp":1694454146000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.13947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,19]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1111\/cas.13947"],"URL":"https:\/\/doi.org\/10.1111\/cas.13947","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,19]]},"assertion":[{"value":"2018-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}